<DOC>
	<DOC>NCT03065790</DOC>
	<brief_summary>Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.</brief_summary>
	<brief_title>Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Adult patients, at least 18 years of age History of histologically confirmed NHL as assessed per medical record review. At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or FDG PET/CT. Recommended to start lenalidomide. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to studyspecific procedures. Females who are pregnant or breastfeeding at the time of screening will not be eligible for this study. Female participants of childbearing potential will have a urine or serum pregnancy test at the time of the screening visit. Inability to tolerate imaging procedures in the opinion of the investigator or treating physician. Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>